tiprankstipranks
Gilead Sciences (GILD)
NASDAQ:GILD
US Market
GILD
Gilead Sciences
RESEARCH TOOLSreports

Gilead Sciences (GILD) Stock Forecast & Price Target

13,826 Followers
See the Price Targets and Ratings of:

GILD Analyst Ratings

Strong Buy
22Ratings
Strong Buy
17 Buy
5 Hold
0 Sell
Based on 22 analysts giving stock ratings to
Gilead
Sciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GILD Stock 12 Month Forecast

Average Price Target

$158.79
▲(12.19% Upside)
Based on 22 Wall Street analysts offering 12 month price targets for Gilead Sciences in the last 3 months. The average price target is $158.79 with a high forecast of $180.00 and a low forecast of $123.00. The average price target represents a 12.19% change from the last price of $141.54.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"99":"$99","140":"$140","181":"$181","119.5":"$119.5","160.5":"$160.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$180.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":158.79,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$158.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":123,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$123.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[99,119.5,140,160.5,181],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,140.3,143.35384615384618,146.40769230769232,149.46153846153848,152.51538461538462,155.56923076923078,158.62307692307692,161.6769230769231,164.73076923076923,167.7846153846154,170.83846153846153,173.8923076923077,176.94615384615383,{"y":180,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,140.3,141.7223076923077,143.1446153846154,144.56692307692308,145.98923076923077,147.41153846153847,148.83384615384617,150.25615384615384,151.67846153846153,153.10076923076923,154.52307692307693,155.9453846153846,157.3676923076923,{"y":158.79,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,140.3,138.9692307692308,137.63846153846154,136.30769230769232,134.97692307692307,133.64615384615385,132.31538461538463,130.98461538461538,129.65384615384616,128.32307692307694,126.99230769230769,125.66153846153847,124.33076923076923,{"y":123,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":108.397,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.575,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.089,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 67,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.608,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.031,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 66,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.825,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.797,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.331,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.816,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.046,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":142.083,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.182,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140.3,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$180.00Average Price Target$158.79Lowest Price Target$123.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on GILD
Joseph Stringer
Needham
Needham
$170
Buy
20.11%
Upside
Reiterated
04/08/26
Gilead’s Tubulis Acquisition: Building an ADC Oncology Franchise and Enhancing Risk‑Reward for GILD Shares
Truist Financial Analyst forecast on GILD
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
04/08/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Viatris (NASDAQ: VTRS) and Insmed (NASDAQ: INSM)
Oppenheimer Analyst forecast on GILD
Matthew Biegler
Oppenheimer
Oppenheimer
$165
Buy
16.57%
Upside
Reiterated
04/08/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Nuvalent (NASDAQ: NUVL) and Innoviva (NASDAQ: INVA)
UBS Analyst forecast on GILD
Michael Yee
UBS
UBS
$175
Buy
23.64%
Upside
Reiterated
04/08/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD) and Soleno Therapeutics (NASDAQ: SLNO)
BMO Capital Analyst forecast on GILD
Evan Seigerman
BMO Capital
BMO Capital
$160→$174
Buy
22.93%
Upside
Reiterated
04/07/26
Gilead Sciences: Strategic Oncology Expansion and Undervalued Growth Opportunity Driving Buy Rating
Goldman Sachs Analyst forecast on GILD
Salveen Richter
Goldman Sachs
Goldman Sachs
$125
Hold
-11.69%
Downside
Reiterated
04/07/26
Balancing Strategic Oncology Expansion and Execution Risk: Why Gilead’s Tubulis Deal Supports a Hold Rating
RBC Capital Analyst forecast on GILD
Brian Abrahams
RBC Capital
RBC Capital
$118→$123
Hold
-13.10%
Downside
Reiterated
04/07/26
Gilead price target raised to $123 from $118 at RBC CapitalGilead price target raised to $123 from $118 at RBC Capital
Leerink Partners Analyst forecast on GILD
Daina Graybosch
Leerink Partners
Leerink Partners
$129
Buy
-8.86%
Downside
Reiterated
04/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Cantor Fitzgerald Analyst forecast on GILD
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
$155
Buy
9.51%
Upside
Reiterated
04/05/26
Gilead Sciences (GILD) Gets a Buy from Cantor Fitzgerald
Bernstein Analyst forecast on GILD
Courtney Breen
Bernstein
Bernstein
$160
Buy
13.04%
Upside
Reiterated
04/03/26
Gilead Sciences (GILD) Receives a Buy from Bernstein
Scotiabank Analyst forecast on GILD
Louise Chen
Scotiabank
Scotiabank
$177
Buy
25.05%
Upside
Reiterated
03/24/26
Scotiabank Reaffirms Their Buy Rating on Gilead Sciences (GILD)
Bank of America Securities Analyst forecast on GILD
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$162
Buy
14.46%
Upside
Reiterated
03/20/26
Buy Rating on Gilead Driven by HIV Franchise Momentum and Upside from Yeztugo and Biktarvy
Barclays Analyst forecast on GILD
Emily Field
Barclays
Barclays
$155
Hold
9.51%
Upside
Assigned
03/12/26
Analysts Offer Insights on Healthcare Companies: Korro Bio (NASDAQ: KRRO), Oruka Therapeutics (NASDAQ: ORKA) and Gilead Sciences (NASDAQ: GILD)
Jefferies Analyst forecast on GILD
Akash Tewari
Jefferies
Jefferies
$180
Buy
27.17%
Upside
Initiated
03/10/26
Gilead initiated with a Buy at JefferiesGilead initiated with a Buy at Jefferies
Citi Analyst forecast on GILD
Geoff Meacham
Citi
Citi
$156
Buy
10.22%
Upside
Reiterated
02/23/26
Citi Reaffirms Their Buy Rating on Gilead Sciences (GILD)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on GILD
Joseph Stringer
Needham
Needham
$170
Buy
20.11%
Upside
Reiterated
04/08/26
Gilead’s Tubulis Acquisition: Building an ADC Oncology Franchise and Enhancing Risk‑Reward for GILD Shares
Truist Financial Analyst forecast on GILD
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
04/08/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Viatris (NASDAQ: VTRS) and Insmed (NASDAQ: INSM)
Oppenheimer Analyst forecast on GILD
Matthew Biegler
Oppenheimer
Oppenheimer
$165
Buy
16.57%
Upside
Reiterated
04/08/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Nuvalent (NASDAQ: NUVL) and Innoviva (NASDAQ: INVA)
UBS Analyst forecast on GILD
Michael Yee
UBS
UBS
$175
Buy
23.64%
Upside
Reiterated
04/08/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD) and Soleno Therapeutics (NASDAQ: SLNO)
BMO Capital Analyst forecast on GILD
Evan Seigerman
BMO Capital
BMO Capital
$160→$174
Buy
22.93%
Upside
Reiterated
04/07/26
Gilead Sciences: Strategic Oncology Expansion and Undervalued Growth Opportunity Driving Buy Rating
Goldman Sachs Analyst forecast on GILD
Salveen Richter
Goldman Sachs
Goldman Sachs
$125
Hold
-11.69%
Downside
Reiterated
04/07/26
Balancing Strategic Oncology Expansion and Execution Risk: Why Gilead’s Tubulis Deal Supports a Hold Rating
RBC Capital Analyst forecast on GILD
Brian Abrahams
RBC Capital
RBC Capital
$118→$123
Hold
-13.10%
Downside
Reiterated
04/07/26
Gilead price target raised to $123 from $118 at RBC CapitalGilead price target raised to $123 from $118 at RBC Capital
Leerink Partners Analyst forecast on GILD
Daina Graybosch
Leerink Partners
Leerink Partners
$129
Buy
-8.86%
Downside
Reiterated
04/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Cantor Fitzgerald Analyst forecast on GILD
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
$155
Buy
9.51%
Upside
Reiterated
04/05/26
Gilead Sciences (GILD) Gets a Buy from Cantor Fitzgerald
Bernstein Analyst forecast on GILD
Courtney Breen
Bernstein
Bernstein
$160
Buy
13.04%
Upside
Reiterated
04/03/26
Gilead Sciences (GILD) Receives a Buy from Bernstein
Scotiabank Analyst forecast on GILD
Louise Chen
Scotiabank
Scotiabank
$177
Buy
25.05%
Upside
Reiterated
03/24/26
Scotiabank Reaffirms Their Buy Rating on Gilead Sciences (GILD)
Bank of America Securities Analyst forecast on GILD
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$162
Buy
14.46%
Upside
Reiterated
03/20/26
Buy Rating on Gilead Driven by HIV Franchise Momentum and Upside from Yeztugo and Biktarvy
Barclays Analyst forecast on GILD
Emily Field
Barclays
Barclays
$155
Hold
9.51%
Upside
Assigned
03/12/26
Analysts Offer Insights on Healthcare Companies: Korro Bio (NASDAQ: KRRO), Oruka Therapeutics (NASDAQ: ORKA) and Gilead Sciences (NASDAQ: GILD)
Jefferies Analyst forecast on GILD
Akash Tewari
Jefferies
Jefferies
$180
Buy
27.17%
Upside
Initiated
03/10/26
Gilead initiated with a Buy at JefferiesGilead initiated with a Buy at Jefferies
Citi Analyst forecast on GILD
Geoff Meacham
Citi
Citi
$156
Buy
10.22%
Upside
Reiterated
02/23/26
Citi Reaffirms Their Buy Rating on Gilead Sciences (GILD)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Gilead Sciences

3 Months
xxx
Success Rate
12/14 ratings generated profit
86%
Average Return
+9.54%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 85.71% of your transactions generating a profit, with an average return of +9.54% per trade.
1 Year
Courtney BreenBernstein
Success Rate
14/14 ratings generated profit
100%
Average Return
+30.49%
Copying Courtney Breen's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +30.49% per trade.
2 Years
xxx
Success Rate
14/14 ratings generated profit
100%
Average Return
+36.19%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +36.19% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GILD Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
0
0
0
0
Buy
47
41
53
50
38
Hold
8
5
10
10
10
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
55
46
63
60
48
In the current month, GILD has received 38 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. GILD average Analyst price target in the past 3 months is 158.79.
Each month's total comprises the sum of three months' worth of ratings.

GILD Financial Forecast

GILD Earnings Forecast

Next quarter’s earnings estimate for GILD is $1.90 with a range of $1.73 to $2.07. The previous quarter’s EPS was $1.86. GILD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.
Next quarter’s earnings estimate for GILD is $1.90 with a range of $1.73 to $2.07. The previous quarter’s EPS was $1.86. GILD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.

GILD Sales Forecast

Next quarter’s sales forecast for GILD is $6.91B with a range of $6.50B to $7.26B. The previous quarter’s sales results were $7.96B. GILD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.
Next quarter’s sales forecast for GILD is $6.91B with a range of $6.50B to $7.26B. The previous quarter’s sales results were $7.96B. GILD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.

GILD Stock Forecast FAQ

What is GILD’s average 12-month price target, according to analysts?
Based on analyst ratings, Gilead Sciences’s 12-month average price target is 158.79.
    What is GILD’s upside potential, based on the analysts’ average price target?
    Gilead Sciences has 12.19% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is GILD a Buy, Sell or Hold?
          Gilead Sciences has a consensus rating of Strong Buy which is based on 17 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Gilead Sciences’s price target?
            The average price target for Gilead Sciences is 158.79. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $180.00 ,the lowest forecast is $123.00. The average price target represents 12.19% Increase from the current price of $141.54.
              What do analysts say about Gilead Sciences?
              Gilead Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.
                How can I buy shares of GILD?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.